Last Verified: | April/30/2020 |
First Submitted: | May/23/2020 |
Estimated Enrollment Submitted: | May/26/2020 |
First Posted: | May/27/2020 |
Last Update Submitted: | May/26/2020 |
Last Update Posted: | May/27/2020 |
Actual Study Start Date: | May/20/2020 |
Estimated Primary Completion Date: | December/30/2020 |
Estimated Study Completion Date: | December/30/2020 |
Study Type: | Interventional |
Allocation: | N/A |
: | In this cohort study, all health workers of the Maternal-Perinatal Hospital "Mónica Pretelini Sáenz", with symptoms of SARS-CoV-2 will be treated promptly with nitazoxanide. |
Primary Purpose: | Treatment |
Masking: | None (Open Label) |
Arm | Intervention/treatment |
---|---|
Experimental: Nitazoxanide early treatment Health workers with symptoms of COVID-19 not requiring hospitalization will receive an early treatment with nitazoxanide. | Drug: Nitazoxanide early treatment Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days. |
Ages Eligible for Study: | 18 Years to 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Criteria: | Inclusion Criteria: - COVID-19 positive patients by clinical criteria. Exclusion Criteria: - Patients who have inherent contraindications to nitazoxanide. - Patients with inflammatory bowel disease. |